In brief: Rockeby, GTG, PharmAust, Mimotopes, Solbec
04 July, 2005 by Ruth BeranRockeby Biomed (ASX:RBY) has lodged a prospectus to raise AUD$1.78 million through a non-renounceable one-for-one share rights issue. The issue price for each share is $0.01 and the company expects the capital to see it through to the end of financial year 2006.
BioProspect cops Euro setback
01 July, 2005 by Graeme O'NeillBrisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Apollo Life Sciences lists at premium
01 July, 2005 by Ruth BeranSydney-based biopharmaceutical Apollo Life Sciences (ASX:AOP) has made a stellar debut on the ASX, at a 54 per cent premium to its offer price.
Peplin gears up for skin drug trials
30 June, 2005 by Graeme O'NeillBrisbane's Peplin Biotech (ASX:PEP) has enrolled the last of 60 Australian patients for its Phase IIa clinical trial of its topical PEP005 treatment for actinic keratoses (AKs) -- pre-cancerous, dry, scaly areas of sun-damaged skin.
CBio opens new labs, outlines development plans
30 June, 2005 by Graeme O'NeillBrisbane biopharma CBio has broken the proverbial bottle of champagne over the bows of its new laboratory and office premises at Brisbane Technology Park, and with Commonwealth P3 grant in hand, is ready to "forge ahead" with developing its novel anti-inflammatory molecule.
In brief: Prima, SciGen, Sonic
30 June, 2005 by Ruth BeranThe executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
Avexa back to the drawing board on hepatitis B program
30 June, 2005 by Ruth BeranMelbourne-based biotech Avexa (ASX:AVX) has been forced to rethink its plans to develop its reformulated hepatitis B candidate AVX491.
Progen hires Burrill as PI-88 heads to market
29 June, 2005 by Graeme O'NeillBrisbane cancer-drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) has appointed San Francisco's Burrill and Co as matchmaker to sift its crammed dance card for a partner to take its promising angiogenesis inhibitor PI-88 to the market.
EvoGenix to list on ASX in August
29 June, 2005 by Ruth BeranAntibody therapeutics company EvoGenix will open its initial public offering within a week and list on the ASX in early to mid-August, with the aim of raising AUD$9 million.
In brief: CSL, Progen Industries, Mayne Group
28 June, 2005 by Ruth BeranCSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12.
FDA approves first 'ethnic medicine'
28 June, 2005 by Kevin DaviesThe FDA, as expected, has followed the recommendation of an advisory panel last week and approved the heart drug BiDil, which clinical data have shown works well in African-Americans but poorly in other populations.
Medical Developments share price boosted by Penthrox trial
28 June, 2005 by Ruth BeranMelbourne based Medical Developments International (ASX:MVP) believes the launch of its Penthrox Inhaler into the Australian dentistry market caused a share price rise from $0.745 on June 24, to $0.87 on June 27, prompting the ASX to issue the company with a 'speeding ticket'.
In brief: ChemGenex Pharmaceuticals, Novogen, Peptech
27 June, 2005 by Ruth BeranChemGenex Pharmaceuticals (ASX:CXS) has received approval to list on the NASDAQ SmallCap Market under the ticker CXSP.
EU ministers uphold sovereign right to ban GMOs
27 June, 2005 by Ruth BeranEU environment ministers dealt a blow to efforts to get more GMO crops grown in Europe as they agreed to uphold eight national bans on genetically modified maize and rapeseed types.
Ai Scientific secures major Italian order
27 June, 2005 by Ruth BeranBrisbane-based clinical automation systems manufacturer, Ai Scientific, has secured a multi-million dollar order from Italian distributor, Medical Systems.
